CIRIUM
18.5.2022 13:32:08 CEST | Business Wire | Press release
Cirium , the aviation analytics company, and travel data analytics firm, 3Victors today announced a reseller partnership to enable Cirium to bring together flight schedules and passenger traffic data with online search data to interpret, understand and forecast passenger demand for airports and DMOs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220518005656/en/
“Cirium and 3Victors share the mission to revolutionize the way the travel industry forecasts future demand,” said Kim Gesch, VP Airline Planning at Cirium. “Airlines and airports worldwide have long used the Diio by Cirium suite of products for network and traffic analysis. We have invested in the products and have enhanced the quality of our schedules, traffic, and fares data to ensure we maintain our leading position in the market.”
Chris Zando, CEO at 3Victors said: “Both 3Victors and Cirium are focused on high quality data science to bring real-time insights to commercial decision-making for the industry. The combination of both our capabilities provides the most dynamic forecasting in the market and at a time when it is most needed.”
Travel demand models have traditionally been built by comparing current bookings for flights against historical trends. Ticket prices were raised and lowered based on indicators from these models to ensure a flight was booked at optimum fare levels. Post-pandemic, changes to traveler booking behavior means past booking patterns may no longer be reliable as a guide to future demand.
Cirium and 3Victors will join forces to offer the most complete solution for analyzing future traffic, monitoring trends across time and detecting emerging opportunities. The offering will include the Diio by Cirium flight schedules, traffic and fares data alongside 3Victors DemandView search data, providing the most accurate forecast as possible.
This is particularly important for airports seeking better insights to retain and gain air service or DMOs wanting to optimize their marketing campaigns and traveler conversion rates.
3Victors’ search data is captured from more than half a million global touchpoints, including when a prospective traveler visits traditional or online travel agency, meta search, or travel search engine: or searches for flights. The most advanced data science is applied to interpret the traveler behavior, which provides a clear demand signal for flight bookings.
An example using 3Victors data shows that on a recent date there were large spikes in domestic demand originating in the UK and US, along with output showing year-over-year variation. If historical trends alone were used to forecast travel demand, the spikes in travel being seen in 2022 to date would not have been forecast.
Said Cirium’s Gesch: “Pairing Cirium’s capabilities with 3Victors’ contemporary travel demand insights means we can offer clients worldwide the most advanced solution to determine accurate traveler intent, monitor passenger trends, and identify correlations between what travelers are searching and actually booking.”
Ends
About Cirium
Cirium brings together powerful data and analytics to keep the world moving. Delivering insight, built from decades of experience in the sector, enabling travel companies, aircraft manufacturers, airports, airlines and financial institutions, among others, to make logical and informed decisions which shape the future of travel, growing revenues and enhancing customer experiences. Cirium is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.
For further information please follow Cirium updates on LinkedIn or Twitter or visit www.cirium.com
About 3Victors
3Victors has built the industry’s first travel data analytics as a service platform in the Cloud. 3V’s proprietary 360° view of the travel landscape is the nexus between data volume, variety and velocity. 3V delivers market-leading data coverage and real-time analytics and insights, empowering companies with actionable intelligence.
For further information please follow 3Victors on LinkedIn or visit https://www.3victors.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220518005656/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom